Transgenomic (TBIO) Reports Q2 Loss of $0.10/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Transgenomic Reports Second Quarter 2016 Financial Results
August 12, 2016 4:05 PM EDTConference Call to be Held at 5:00 PM Eastern Time Today
OMAHA, Neb.--(BUSINESS WIRE)-- Transgenomic, Inc. (TBIO), (NASDAQ: TBIO) today reported financial results for the second quarter ended June 30, 2016, and provided a business update.
Second Quarter Financial Results from Continuing OperationsNet sales for the second quarter of 2016 were $0.5 million as compared with $0.4 million for the same period in 2015. Sales of the Companys contract laboratory services were flat year over year. The slight increase in total sales for the current year reflects increased oncology and grant revenues.... More
